Quality of life of type 2 diabetes patients in a tertiary care hospital in southern part of India, Shimoga, Karnataka: a cross-sectional study

Santosh, Anasuri; Koppad, Raghavendraswamy; Chandrashekar, SV; Revathy, Revathy

doi:10.18203/2394-6040.ijcmph20161855

Cited by 3 publications

(6 citation statements)

References 7 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was determined that patients without complications related to diabetes had high quality of life related to physical functioning (p<0.05). This result of the study is compatible with the literature (23,32,33,37,41). Diabetes complications negatively affect especially physical functioning and cause certain levels of physical limitations.…”

Section: Discussionsupporting

confidence: 91%

“…In another study revealed that physical component of health-related quality of life of individuals with 4). Similar to the results of this study, it was reported in the studies that male patients had high quality of life related to physical functioning, social functioning, mental health, pain and general health (32)(33)(34). It was found in the literature that male patients had high mean scores in different scale subscales related to quality of life, which supports these results (35).…”

Section: Discussionsupporting

confidence: 91%

“…The quality of life of diabetic patients under 65 years of age was found to be high in the a study (p<0.05) (35). In another study found that there was a statistically significant difference between the age variable and general health and energy subscales (p<0.05) (32). Similarly, in a study, it is stated that the quality of life decreased with advancing age and the individuals aged 70 and over constituted the group having the lowest quality of life (p<0.05) (36).…”

Section: Discussionmentioning

confidence: 80%

“…In another study reported that the patients using only OAD obtained significantly high scores in energy, social functioning, and mental health subscales and general quality of life scores (p<0.05) (32). This result of the study was thought to be associated with treatment compliance rather than treatment type.…”

Section: Discussionmentioning

confidence: 81%

See 3 more Smart Citations

Tip-2 Diyabetli Hastalarda Öz Yeterlilik Düzeyinin Yaşam Kalitesine Etkisi

ARSLAN

Özdelikara

2023

Turk J Diab Obes

View full text Add to dashboard Cite

Aim: This study was conducted to determine the effect of self-efficacy level on quality of life in patients with type-2 diabetes. Material and Methods: This descriptive type study was conducted with 150 patients with type-2 diabetes who received inpatient treatment in a University Health Practice and Research Center between October 2017 and February 2018. The data were collected using information form, Diabetes Management Self-Efficacy Scale, and Short Form-36 (Short Form-36/SF-36) Quality of Life Questionnaire. Percentage, mean, Kruskal Wallis and Mann Whitney U tests, and Spearman correlation analysis were used to analyze the data. Results: It was determined in the study that self-efficacy scale total score in diabetes was 54.16±14.65; the highest mean score among the subscales of the quality of life questionnaire belonged to mental health (20.17±4.79). It was determined that there was a positive significant correlation between the self-efficacy total score in diabetes of the patients and the physical functioning, physical role difficulty, general health, energy, social function, emotional role difficulty and mental health subscales of SF-36 quality of life questionnaire (p

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 81%

See 2 more Smart Citations

Tip-2 Diyabetli Hastalarda Öz Yeterlilik Düzeyinin Yaşam Kalitesine Etkisi

ARSLAN

Özdelikara

2023

Turk J Diab Obes

View full text Add to dashboard Cite

show abstract

“…Other studies have also reported a higher quality of life among dieters and exercisers. 17,25,26 This may be due to diabetes-related symptoms and complications emerging less or later among patients with good adherence to lifestyle modifications. Akyol et al found that there was a negative significant correlation between nutritional literacy individuals with diabetes.…”

Section: Discussionmentioning

confidence: 99%

Birinci basamakta tip 2 diyabet hastalarının ilaç uyumu ve yaşam kalitesi ilişkisi: Kesitsel bir çalışma

ALÇINAR,

ŞAHİN

2023

Turkish Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Aim: This study aimed to evaluate the association between medication adherence and quality of life in patients with diabetes receiving primary healthcare centers. Method: Patients with type 2 diabetes, aged 18-65 between July and October 2022, were included in this cross-sectional study. A questionnaire including sociodemographic characteristics, the Diabetes Quality of Life (DQOL) scale, and the Modified Morisky Scale (MMS) were used. Results: Two hundred nine patients with type 2 diabetes participated in this study. The mean age of the participants was 53.5±9.2 years, and 51.7% were women. The mean DQOL score of the participants was 3.8±0.7. Quality of life was higher among married participants and those with medium-high income, diagnosed with diabetes <5 years previously, without diabetes complications, using only oral antidiabetic drugs for the treatment of diabetes, who regularly used diabetes medications, who dieted and exercised for diabetes, and who regularly attended diabetes follow-up (p<0.05). Quality of life was also higher in those with better MMS showing a better medication adherence motivation and knowledge levels (p<0.01). Conclusions: Participants' medication adherence motivation and knowledge levels were associated with an increased quality of life. Admission to primary healthcare centers for diabetes follow-up was also associated with a higher quality of life.

show abstract

Effect of Gliclazide or Gliclazide plus Metformin Combination on Glycemic Control in Patients with T2DM in India: A Real-World, Retrospective, Longitudinal, Observational Study from Electronic Medical Records

Polavarapu

Kale

Sethi

et al. 2020

Drugs - Real World Outcomes

View full text Add to dashboard Cite

Background The efficacy of gliclazide has been reported in clinical trials in India. However, real-world data on the effectiveness of gliclazide in India is unavailable. Objective To provide real-world evidence regarding the effectiveness of gliclazide or gliclazide + metformin fixed-dose combination or separate medications, used either as monotherapy or as the latest add-on to other antihyperglycemic agents in reducing glycated hemoglobin (HbA1c) levels in Indian patients with type 2 diabetes mellitus (T2DM). Methods Electronic medical record data of adult patients who were diagnosed with T2DM who were newly initiated on or had been prescribed gliclazide or gliclazide + metformin combination for < 30 days as monotherapy or as add-on therapy to other antihyperglycemic agents, and had HbA1c ≥ 6.5% were retrospectively analyzed. Mean change in HbA1c from baseline was the primary endpoint. Secondary endpoints were assessment of dosages and formulations of gliclazide or gliclazide + metformin prescribed in the HbA1c spectrum and antihyperglycemic agents to which gliclazide or gliclazide + metformin was added as an adjunct. Readings were obtained before initiating gliclazide or gliclazide + metformin and after at least 90 days of treatment with gliclazide or gliclazide + metformin. Results Included patients ( n = 498) were categorized into gliclazide only ( n = 66), gliclazide + metformin only ( n = 179), gliclazide add-on ( n = 169), and gliclazide + metformin add-on ( n = 84) groups. Mean (95% confidence interval [CI]) change in HbA1c among patients with baseline HbA1c > 7% was − 0.8% (− 1.26, − 0.34) in gliclazide only group; − 1.6% (− 1.89, − 1.31; p < 0.001) in gliclazide + metformin group; − 1.2% (− 1.50, − 0.90; p < 0.001) in add-on gliclazide group; and − 1.4% (− 1.75, − 1.05; p < 0.001) in add-on gliclazide + metformin group. Gliclazide once daily was the most prescribed regimen in the gliclazide only group (72.7%), with 60 mg being the most prescribed modified-release dose (62.5%). Gliclazide + metformin twice daily was the most prescribed regimen in the gliclazide + metformin group (69.3%) with 80 mg + 500 mg being the most prescribed immediate-release dose (62.9%). Gliclazide and gliclazide + metformin were most added as an adjunct to existing prescriptions of biguanides (83.4%) or insulin (64.3%), respectively. Conclusion Gliclazide or gliclazide + metformin prescribed as mono- or add-on therapy during routine clinical practice effectively reduced HbA1c in Indian patients with T2DM, thus validating the use of gliclazide and gliclazide + metformin for managing T2DM in India.

show abstract

Quality of life of type 2 diabetes patients in a tertiary care hospital in southern part of India, Shimoga, Karnataka: a cross-sectional study

Cited by 3 publications

References 7 publications

Tip-2 Diyabetli Hastalarda Öz Yeterlilik Düzeyinin Yaşam Kalitesine Etkisi

Tip-2 Diyabetli Hastalarda Öz Yeterlilik Düzeyinin Yaşam Kalitesine Etkisi

Birinci basamakta tip 2 diyabet hastalarının ilaç uyumu ve yaşam kalitesi ilişkisi: Kesitsel bir çalışma

Effect of Gliclazide or Gliclazide plus Metformin Combination on Glycemic Control in Patients with T2DM in India: A Real-World, Retrospective, Longitudinal, Observational Study from Electronic Medical Records

Contact Info

Product

Resources

About